Supplementary materials: Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada

dataset

posted on 2024-04-15, 14:22 authored by Virender Bhan, Fraser Clift, Moogeh Baharnoori, Kimberly Thomas, Barkha P. Patel, Francois Blanchette, Nicholas Adlard, Umakanth Vudumula, Kapil Gudala, Nikkita Dutta, Daniel Grima, Soukaina Mouallif, Fatine Farhan

These are peer-reviewed supplementary materials for the article 'Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada' published in the Journal of Comparative Effectiveness Research.

Supplementary Table 1: Annual natural history transition probabilities (%) for EDSS states
Supplementary Table 2: EDSS-dependent mortality multiplier and disability weights for MS and number of hospitalization days per year
Supplementary Table 3: Productivity loss per year due to MS
Supplementary Table 4: Treatment efficacy and discontinuation probabilities for ofatumumab and comparators versus BSC from the network meta-analysis
Supplementary Table 5: Costs by health state
Supplementary Table 6: Drug administration, monitoring, and adverse event costs
Supplementary Table 7: Drug administration costs
Supplementary Table 8: Drug monitoring costs
Supplementary Figure 1: Patient time (in years) in each EDSS health state over 10 years for first-line and second-line treatments without treatment switching or delay.
Supplementary Figure 2: YLD and YLL over 10 years for all first-line and second-line treatments without treatment switching or delay.
Supplementary Figure 3: Sensitivity Analysis results for Ofatumumab versus Ocrelizumab at 10-years.
Supplementary Figure 4: Sensitivity Analysis results for Ofatumumab versus Teriflunomide at 10-years.
Supplementary Figure 5: Sensitivity Analysis results for Ofatumumab versus Dimethyl Fumarate at 10-years.
Supplementary Figure 6: Sensitivity Analysis results for Ofatumumab versus Glatiramer Acetate at 10-years.
Supplementary Figure 7: Sensitivity Analysis results for Ofatumumab versus Avonex at 10-years.
Supplementary Figure 8: Sensitivity Analysis results for Ofatumumab versus Rebif 44 at 10-years.
Supplementary Figure 9: Sensitivity Analysis results for Ofatumumab versus Betaseron at 10-years.
Supplementary Figure 10: Sensitivity Analysis results for Ofatumumab versus Extavia at 10-years.
Supplementary Figure 11: Sensitivity Analysis results for Ofatumumab versus BSC at 10-years.
Supplementary Figure 12: Sensitivity Analysis results for Ofatumumab versus Cladribine at 10-years.
Supplementary Figure 13: Sensitivity Analysis results for Ofatumumab versus Natalizumab at 10-years.
Supplementary Figure 14: Sensitivity Analysis results for Ofatumumab versus Fingolimod at 10-years.

Aim: The costs and consequences of initial and delayed ofatumumab treatment were evaluated in relapsing-remitting multiple sclerosis with active disease in Canada. Materials & methods: A Markov cohort model was used (10-year horizon, annual cycle length, 1.5% discounting). Scenario analyses examined ofatumumab as first-line treatment versus 3 and 5 years following switch from commonly used first-line therapies. Results: Ofatumumab resulted in improvements in clinical outcomes (relapses and disease progression) and productivity (employment and full-time work), and reduction of economic burden (administration, monitoring and non-drug costs) that were comparable to other high-efficacy therapies (ocrelizumab, cladribine and natalizumab). Switching to ofatumumab earlier in the disease course may improve these outcomes. Conclusion: Results highlight the value of a high-efficacy therapy such as ofatumumab as initial treatment (i.e., first-line) in newly diagnosed relapsing-remitting multiple sclerosis patients with active disease.